Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test 2021-05-27 21:00
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis (IPF) shows promising result in early stage clinical test 2021-05-24 16:59
Daewoong showed improved performance both sales and earnings in Q1 2021-05-07 21:00
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study 2020-11-06 22:00
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide 2020-10-29 21:00
Daewoong Pharmaceutical's COVID-19 Treatment Candidate Also Highly Effective against Influenza Virus 2020-10-28 22:36
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic' 2020-10-27 21:00
Daewoong Pharmaceutical's new SGLT2 inhibitor for diabetes treatment demonstrates remarkable effect in phase 2 clinical trial 2020-09-29 15:00
Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment 2020-09-28 20:00
Daewoong Pharmaceutical Acquires Halal Certification for 'Easyef' through Daewoong Infion 2020-05-27 10:00
Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker 2020-05-11 08:00
1 2 3